| Original language | English |
|---|---|
| Pages (from-to) | 939-940 |
| Number of pages | 2 |
| Journal | JAMA Oncology |
| Volume | 7 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1 Jun 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JAMA Oncology, Vol. 7, No. 6, 01.06.2021, p. 939-940.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Patient Willingness to Enroll in Cancer Clinical Trials When Sites Return to Prepandemic Status
AU - Bayle, Arnaud
AU - Barlesi, Fabrice
AU - Massard, Christophe
N1 - Funding Information: Conflict of Interest Disclosures: Dr Barlesi reported personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche, Novartis, Merck, Mirati Therapeutics, Merck Sharp & Dohme, Pierre Fabre, Pfizer, Seattle Genetics, and Takeda. Dr Massard reported receiving consultant/advisory fees from Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, and Orion; and as part of the Drug Development Department (DITEP), principal/subinvestigator of clinical trials for AbbVie, Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argenx BVBA, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, Bbb Technologies Bv, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan Apollo, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Therapeutics, GamaMabs Pharma, Genentech, GlaxoSmithKline, H3 Biomedicine, F. Hoffmann-La Roche AG, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin, Lilly France, Loxo Oncology, Lytix Biopharma, MedImmune, Menarini Ricerche, Merck Sharp & Dohme–Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners AG, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology NV, Oncoethix, Oncopeptides, Orion Pharma, OSE Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi-Aventis, Seattle Genetics, Sotio AS, Syros Pharmaceuticals, Taiho Pharma, Tesaro, and Xencor; research grants from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Onxeo, Pfizer, Roche, and Sanofi; and nonfinancial support (drug supplied) from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, MedImmune, Merck, NH TherAguix, Onxeo, Pfizer, and Roche. No other disclosures were reported. Funding Information: the submitted work. Dr Langer reported personal fees from Merck, Genentech, Roche, Lilly, Takeda, Gilead, and AstraZeneca and grants from Trizell, Merck, AstraZeneca, and Amgen outside the submitted work. Dr Mamtani reported personal fees from Astellas and Seagen, grants from Merck, and travel fees from Flatiron Health outside the submitted work. Dr Aggarwal reported personal fees from AstraZeneca, Bristol Myers Squibb, Celgene, Merck, and Roche outside the submitted work. No other disclosures were reported.
PY - 2021/6/1
Y1 - 2021/6/1
UR - http://www.scopus.com/inward/record.url?scp=85103556518&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2021.0376
DO - 10.1001/jamaoncol.2021.0376
M3 - Letter
C2 - 33792621
AN - SCOPUS:85103556518
SN - 2374-2437
VL - 7
SP - 939
EP - 940
JO - JAMA Oncology
JF - JAMA Oncology
IS - 6
ER -